BIOMERIEUX
FREURBIOMERIEUX (PA:BIM) — Diagnostics & Research. Biržu skaits, kurās tiek tirgotas uzņēmuma akcijas: 4. Šajā lapā — cena un grafiks, dividendes, lielākie akcionāri un akciju skaita vēsture.
Par Uzņēmumu
- Tīmekļvietne
- biomerieux.fr
- Nozare
- Healthcare · Diagnostics & Research
- Galvenā Mītne
- Marcy-l'Étoile, France
- Izpilddirektors
- Pierre Boulud
- Darbinieki
- 14 562
- Dibināts
- 1963
- Apgrozībā Esošās Akcijas
- 117.95 milj.
- Brīvā Apgrozība
- 40.02 milj.
- Tirgus Kapitalizācija
- 9.17 mljrd. EUR
- Iekšējās Personas
- 66.46%
- Institucionālie Investori
- 16.73%
- Juridiskā Forma
- K65D
- ISIN
- FR0013280286
- LEI
- 549300AK8Y0LBIQ4T071
- P/E
- 22.0
- Izmaksas Koeficients
- 24.9%
- FCF
- 586 milj. EUR
- Izmaksas / FCF
- 20%
- Parāds
- 422 milj. EUR0.0 g. FCF
- Dividenžu Stāžs
- 21 g.
- Peļņa, FCF un izmaksātās dividendes — par 12 mēnešiem līdz 30.06.2026 (uzņēmuma jaunākais ziņojums).
Apraksts
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL, a rapid AST system; ETEST, a gradient method on culture media; BIOMERIEUX EPISEQ CS, a whole genome sequencing solution for epidemiologic monitoring; VIDAS, a specific marker of severe bacterial infections/sepsis; and Biomérieux vision suite, a software that provides information to support diagnosis and clinical decision making. It also provides culture media and associated instruments; ARGENE that provides PCR tests for diagnosing viral respiratory diseases; EMAG system and NUCLISENS extraction reagents for DNA and RNA extraction; GENE-UP and VERIFLOW for detection of microorganisms for the food industry; ETEST for manual measurement of minimum inhibitory concentration of an antibiotic; API and RAPIDEC CARBA NP for identification of bacteria and manual antimicrobial susceptibility testing; BIOBALL for quantitative microbiological quality control; CHEMUNEX, a microbiology instrument; ENDONEXT for detection of endotoxins; TEMPO for fluorescence counting of bacteria; and Hybiome, a CLIA technology, as well as lab consultancy service and training modules. The company was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. operates as a subsidiary of Institut Mérieux SA.
Dividendes
BIOMERIEUX (BIM) izmaksā dividendes reizi gadā. Gadā (12 mēneši līdz jaunākajam paziņotajam maksājumam): 0.98 EUR par akciju (maksājumi: 1). Tas ir aptuveni 1.14% no pašreizējās akciju cenas. Nepārtrauktu dividenžu gadi: 21.
| Ex-Datums | Izmaksa | Summa | % | Veids | Tikeris |
|---|---|---|---|---|---|
| 2026-06-09 | 2026-06-11 | 0.9800 EUR | 1.4/1.4 % | — | PA:BIM |
Lielākie Akcionāri
| Turētājs | Daļa | Akcijas | Pārskata Datums |
|---|---|---|---|
| New Economy Fund | 0.86% | 1.02 milj. | 2026-06-30 |
| VANGUARD STAR FUNDS-Vang… | 0.54% | 638 380 | 2026-04-30 |
| Tweedy, Browne Fund Inc.… | 0.41% | 481 731 | 2026-06-30 |
| VANGUARD TAX-MANAGED FUN… | 0.32% | 384 560 | 2026-06-30 |
| iShares Trust-iShares Co… | 0.26% | 304 380 | 2026-07-31 |
| AMERICAN FUNDS INSURANCE… | 0.19% | 226 573 | 2026-06-30 |
| Fidelity Concord Street… | 0.13% | 149 019 | 2026-07-31 |
| Bridge Builder Trust-Bri… | 0.12% | 142 421 | 2026-06-30 |
| iShares Trust-iShares MS… | 0.12% | 142 244 | 2026-07-31 |
| DFA INVESTMENT TRUST CO-… | 0.09% | 109 829 | 2026-04-30 |
| Pacer Advisors, Inc. | 0% | 202 | 2026-06-30 |
